Arcutis Biotherapeutics has recently revealed a significant development regarding its Zoryve roflumilast cream 0.3% for the treatment of plaque psoriasis. The company announced that the cream is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies. This update is effective from July 5.
Access to Millions of Additional Lives
With this latest development, Arcutis Biotherapeutics estimates that the inclusion of Zoryve on CVS Caremark’s national formularies will provide access to an additional 20 million commercial lives in the United States. This broadens the reach and availability of the treatment for individuals suffering from plaque psoriasis.
Specific Coverage Criteria
Arcutis informs that Zoryve is covered for individuals with plaque psoriasis who have a prior history of using a topical steroid. However, for individuals with plaque psoriasis in sensitive skin areas, no prior steroid therapy is required.
A Strong Leap for Arcutis Biotherapeutics
Frank Watanabe, the President and CEO of Arcutis, expressed his enthusiasm for this significant milestone. He mentioned that CVS Caremark is the largest U.S. pharmacy benefit manager to include Zoryve on its national formularies, and the third one to do so since the product’s launch less than a year ago.
Available by Prescription Only
It’s important to note that Zoryve cream is only available by prescription. Patients should consult their healthcare providers to determine if this treatment is suitable for their condition.
For further inquiries, please contact Arcutis Biotherapeutics directly.